

# Mehmet Aalan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5083417/publications.pdf>

Version: 2024-02-01

16  
papers

204  
citations

1163117

8  
h-index

1058476

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus. <i>Journal of Diabetes</i> , 2020, 12, 474-482.	1.8	9
2	Relation of Decreased Circulating Sortilin Levels With Unfavorable Metabolic Profiles in Subjects With Newly Diagnosed Type 2 Diabetes Mellitus. <i>American Journal of the Medical Sciences</i> , 2020, 359, 8-16.	1.1	7
3	Correlation of serum C1q-tumour necrosis factor-related protein 5 levels with metabolic parameters and carotid intima-media thickness in newly diagnosed type 2 diabetes mellitus patients. <i>Hormones</i> , 2020, 19, 559-564.	1.9	0
4	Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2020, 36, 849-853.	1.7	5
5	Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 303-312.	3.3	9
6	Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. <i>Hormones</i> , 2019, 18, 435-442.	1.9	12
7	Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. <i>Endocrine</i> , 2019, 65, 175-183.	2.3	10
8	The relationship between urotensin II and insulin resistance in women with gestational diabetes mellitus. <i>Hormones</i> , 2019, 18, 91-97.	1.9	8
9	Association of decreased C1q/tumor necrosis factor-related protein-5 levels with metabolic and hormonal disturbance in polycystic ovary syndrome. <i>Journal of the Turkish German Gynecology Association</i> , 2019, 20, 89-96.	0.6	6
10	Association of kallistatin with carotid intima-media thickness in women with polycystic ovary syndrome. <i>Minerva Endocrinology</i> , 2018, 43, 236-245.	1.1	7
11	Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. <i>Endocrine Research</i> , 2017, 42, 145-153.	1.2	21
12	Increased adiponin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2016, 85, 910-917.	2.4	38
13	Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. <i>Endocrine</i> , 2016, 53, 271-279.	2.3	40
14	A possible link between luteinizing hormone and macrophage migration inhibitory factor levels in polycystic ovary syndrome. <i>Endocrine Research</i> , 2016, 41, 261-269.	1.2	10
15	Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2016, 32, 218-222.	1.7	12
16	The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS. <i>Gynecological Endocrinology</i> , 2013, 29, 970-973.	1.7	10